These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26911649)

  • 1. Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children.
    Mortensen R; Nissen TN; Fredslund S; Rosenkrands I; Christensen JP; Andersen P; Dietrich J
    Sci Rep; 2016 Feb; 6():22030. PubMed ID: 26911649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
    Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
    Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
    Ozberk V; Pandey M; Good MF
    Hum Vaccin Immunother; 2018; 14(8):2034-2052. PubMed ID: 29873591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG.
    Reglinski M; Lynskey NN; Choi YJ; Edwards RJ; Sriskandan S
    J Infect; 2016 Apr; 72(4):450-9. PubMed ID: 26880087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quest for GAS vaccine.
    Pandey M; Good MF
    Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract]   [Full Text] [Related]  

  • 8. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and assessment of new vaccine candidates for group A streptococcal infections.
    McMillan DJ; Batzloff MR; Browning CL; Davies MR; Good MF; Sriprakash KS; Janulczyk R; Rasmussen M
    Vaccine; 2004 Jul; 22(21-22):2783-90. PubMed ID: 15246612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group A
    Young PG; Raynes JM; Loh JM; Proft T; Baker EN; Moreland NJ
    Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
    Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
    mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
    Schulze K; Medina E; Guzmán CA
    Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.
    Maruggi G; Chiarot E; Giovani C; Buccato S; Bonacci S; Frigimelica E; Margarit I; Geall A; Bensi G; Maione D
    Vaccine; 2017 Jan; 35(2):361-368. PubMed ID: 27939014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus.
    Skwarczynski M; Kamaruzaman KA; Srinivasan S; Zaman M; Lin IC; Batzloff MR; Good MF; Toth I
    Curr Drug Deliv; 2013 Feb; 10(1):39-45. PubMed ID: 22998043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.
    Georgousakis MM; Hofmann A; Batzloff MR; McMillan DJ; Sriprakash KS
    Vaccine; 2009 Nov; 27(48):6799-806. PubMed ID: 19729086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.
    Fritzer A; Senn BM; Minh DB; Hanner M; Gelbmann D; Noiges B; Henics T; Schulze K; Guzman CA; Goodacre J; von Gabain A; Nagy E; Meinke AL
    Infect Immun; 2010 Sep; 78(9):4051-67. PubMed ID: 20624906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
    Guerino MT; Postol E; Demarchi LM; Martins CO; Mundel LR; Kalil J; Guilherme L
    Vaccine; 2011 Oct; 29(46):8250-6. PubMed ID: 21907752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.